165947-48-8

Usage

Uses

Used in Pharmaceutical Industry:
5-(TERT-BUTOXYCARBONYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE-2-CARBOXYLIC ACID is used as a building block for the preparation of various pharmaceuticals and other biologically active molecules. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Research and Development:
5-(TERT-BUTOXYCARBONYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE-2-CARBOXYLIC ACID is also commonly used in the development of new drugs, serving as a key intermediate in the synthesis of novel compounds with potential medicinal properties. Its presence in the synthesis process aids researchers in understanding the structure-activity relationships of newly developed drugs.
Used as a Research Tool:
5-(TERT-BUTOXYCARBONYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-C]PYRIDINE-2-CARBOXYLIC ACID is utilized as a research tool for the study of various biological processes. Its ability to be incorporated into complex molecular structures makes it valuable for investigating the mechanisms of action of potential drug candidates and for probing the interactions between these molecules and their biological targets.

InChI:InChI=1/C13H17NO4S/c1-13(2,3)18-12(17)14-5-4-9-8(7-14)6-10(19-9)11(15)16/h6H,4-5,7H2,1-3H3,(H,15,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 116118-98-0 4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carboxylic acid 
• 110-54-3 hexane 
• 949922-62-7 2-bromo-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylic acid tert-butyl ester 
• 124-38-9 carbon dioxide 
• 28783-41-7 6,7-dihydro-4H-thieno[3,2-c]pyridine hydrochloride 
• 885275-20-7 tert-butyl 4-chloro-5-formyl-3,6-dihydropyridine-1(2H)-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 623564-30-7 5-(tert-butyl) 2-ethyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate 

Downstream Products

• 1135123-74-8 5-(tert-butyl) 2-methyl 6,7-dihydrothieno[3,2-c]pyridine-2,5(4H)-dicarboxylate 

Relevant academic research and scientific papers

Synthesis, characterization and anticancer activity of 5-substituted 4,5,6,7-tetrahydro-N-(tetrahydro-2H-pyran-4-yl)thieno[3,2-c]pyridine-2-carboxamide derivatives

4,5,6,7-Tetrahydrothieno pyridine (THTP) and their derivatives are an important heterocyclic compounds that exhibits various biological activities viz.,antimicrobial activity, antileishmanial activity, antiarrhythmic activity, antiinflammatory activity, antihyperlipidemic activity, antidepressant activity, anticancer activity, antiplatelet activity and antidiabetic etc. The present study describes the synthesis, characterization and in vitro cytotoxic potential against human lung carcinoma of some novel derivatives of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (7A-M) with benzylic and amide substitution on the nitrogen atom of tetrahydro theino pyridine ring. The synthetic steps involves (i) Vilsmeyer protocol in step 1 (ii) formation of tetrahydothieno[3,2-c]pyridine ring in presence of 2-mercaptoacetate in step 2 (iii) alkaline hydrolysis followed by amide coupling with tetrahydro-2H-pyran-4-amine in step 3 and step 4. The newly synthesized compounds 7A-M was sufficiently characterized by 1 H NMR, IR and mass techniques. Furthermore, these derivatives were screened for their in vitro cytotoxic potential against human lung carcinoma (HCT-116) cell line using the MTT assay. Compound 7B (IC50: 69.52 μg) and compound 7K (IC50: 66.35 μg) exhibited significant activity at micro molar concentration when compared to standard drug camptothecin.

Significant Discovery of Tetrahydrothieno[3,2-c]pyridine-2-carboxamide Analogs as Potent P2Y12 Receptor Antagonists

A series of analogs containing tetrahydrothieno[3,2-c]pyridine-2-carboxamide as a building block with numerous alicyclic and aromatic amines were synthesized. All analogs were characterized by spectral analysis and evaluated for their in vitro antiplatelet activity. 4-Fluorophenyl amide derivatives (compounds 8–11) have been found to be most active in the series with respect to prasugrel and aspirin, a third generation antiplatelet agents (P2Y12 receptor antagonists). Docking study also manifested the admirable binding mode of in vitro active compounds 10 and 11 with the target protein. The results may provide a new perception for future pharmacophore with simple design strategy and avoid tedious synthesis of clopidogrel and prasugrel.

Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation

Protein arginine methyltransferases 5 (PRMT5) represents an attractive drug target in epigenetic field for the treatment of leukemia and lymphoma. Here, a series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivatives targeting PRMT5 were designed with structure-based approach and synthesized. Among them, compound 46 showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approximately equivalent with the phase I clinical trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM). Compound 46 also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model. This molecule can serve as an excellent tool compound for probing the biological function of PRMT5.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Compound with platelet aggregation inhibitor activity

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: STR1 wherein R1 represents a group --W--(CH2)i --COOR3, R2 represents a hydrogen atom or a group --W--(CH2)i --COOR3 or --OR4, X represents --CH= or --N=, Y represents (i) a group --(CO)k --N(R5)--Z--, wherein Z represents a bond or a group --(CH2)m --CO-- or a group --(CH2)m --CHR6 --, (ii) a group --(CH2)m --N(R5)--(CO)k --, or (iii) a group --(CO)k -Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom, A represents (i) the following groups (III) or (IV) STR2 B represents a bond, C1-6 alkylene or C2-6 alkenylen.

Tetrahydrothienopyridine derivatives as novel GPIIB/IIIA antagonists

The tetrahydrothienopyridine derivatives were derived from aminomethylcyclohexylcarboxylic acid as a lead moiety. Evaluation of the antiplatelet activity and receptor binding assay revealed that compound 1 (Me3277) was a novel and potent non-peptide and n